Daewoong Pharmaceutical has released the results of a study on the indication of its P-CAB (potassium-competitive acid blockers)-based drug, Fexuclue (fexuprazan hydrochloride), to treat gastritis at the United European Gastroenterology Week (UEGW) 2022.Daewoong said it unveiled the phase 3 clinical
Dong-A ST said Wednesday it released the results of the phase 3 clinical trial of Evogliptin plus three-drug combination therapy at the European Association for the Study of Diabetes (EASD) conference in Stockholm from Sept. 19-23.Professor Yoon Keon-ho of the Department of Endocrine Metabolism at S
Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan), the two breast cancer therapies based on the next-generation antibody-drug conjugates (ADC), will likely take the lead in the cancer’s innovative treatment across the board.The first-generation ADC developed by Roche, Kadcyla (tr
ViGenCell, an immune cell therapy developer, said the Ministry of Food and Drug Safety has granted compassionate use approval for VT-Tri, an acute myeloid leukemia (AML) treatment.Compassionate use permits the use of investigational drugs for treating patients with severe and life-threatening illnes
The Korea Exchange (KRX) held a corporate review committee on Thursday and decided to maintain the listing of SillaJen on the tech-heavy Kosdaq market.With the decision, SillaJen's shares will resume trading on Thursday.The company used to be one of the most prominent local biopharmaceutical compani
Boryung said on Wednesday that its new anticancer drug candidate, BR101801, for treating peripheral T cell lymphoma (PTCL) has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA).Peripheral T cell lymphoma is a malignant tumor originating from T cells, which are immune c
Duchem Bio said it launched FACBC, the world’s first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea.The drug, developed by Nihon Medi Physics, a Japanese pharmaceutical company, is used when conducting positron emission tomography (PET) in patients suspected of having pr
Hugel said Friday that it reapplied to the U.S. Food and Drug Administration (FDA) for marketing approval for Letybo (brand name in Korea: Botulax), its botulinum toxin formulation, to treat forehead wrinkles.Hugel had sought the U.S. permit for Letybo 50 units and 100 units in March 2021.However, t
The Korea Exchange (KRX) held a corporate review committee on Thursday and decided to maintain the listing of Qurient on the tech-heavy Kosdaq market. With the decision, Qurient's shares resumed trading but plummeted on Friday morning.As of 11:00 a.m., the company's shares stood at 15,900 won ($11.2
GC and GSK Korea will jointly sell the latter's new shingles vaccine, Shingrix.According to industry sources, the two companies recently signed a co-promotion contract for Shingrix.GC started training its sales representatives before the full-scale market release possibly as early as the end of 2022
Almost no Korean is getting SK Bioscience's Covid-19 vaccine, SKYCovione, because the vaccine release was too late compared to foreign vaccines, government data showed.According to the 82-week COVID-19 vaccination safety report published by the Korea Disease Control and Prevention Agency (KDCA), 158
Daewoong Pharmaceutical said on Wednesday that it rolled out botulinum toxin "Nuceiva" (domestic product name: Nabota) in the U.K. last month through its partner, Evolus.The U.K. is the largest single market in Europe, accounting for about 30 percent of the European botulinum toxin market worth 650
Lotte Biologics recently had a bitter experience after a fake LinkedIn account posing as a key executive of Bristol-Myers Squibb (BMS) expressed “displeasure over the sale of the latter's plant to Lotte Group.”According to industry sources, a LinkedIn account claiming as Lou Schmukler, president of
The U.S. clinical trial of Icure Pharmaceutical’s donepezil-containing patch-type (percutaneous absorption drug) dementia treatment will be postponed to 2023.On Tuesday, Icure unveiled its research and development progress and new plans by revising its securities report. Icure’s move follows its dec
Korea Pharma said Wednesday that it signed a joint development contract with G2GBIO and Humedix to develop a one-month long-lasting Alzheimer's dementia injection-based treatment called GB-5001.Under the agreement, the three companies will jointly develop a newly improved injection-based drug for tr
Yuyu Pharmaceutical CEO Robert Yu promoted YP-P10, a dry eye syndrome treatment candidate, during the 2022 American Academy of Ophthalmology (AAO) Conference held in Chicago, U.S., from last Friday to Monday, the company said. During the conference, Yu explained YP-P10 to ophthalmologist key opinion
An artificial intelligence (AI)-based new drug development boom has erupted among Korean pharmaceutical companies.According to industry insiders, AI platform makes the new drug development process stable and efficient.The platform provides services such as analyzing data based on extensive researc
The police have begun investigating Ilyang Pharmaceutical on charges of exaggerating the results of a study on Covid-19 treatment candidate to inflate its stock price, local news reports said.According to the reports, the Seoul Metropolitan Police Agency is investigating Ilyang for allegedly violati
Daewoong Pharmaceutical said Wednesday that the company signed a contract with AZothBio to research and develop synthetic lethality anticancer treatments using artificial intelligence on Sept. 16.AZothBio is a new drug-developing AI platform company. The company’s AI-based new drug developing platfo
"Global pharmaceutical companies are constantly finding new ways to develop innovative drugs despite the recent Covid-19 pandemic."Yoshitake Maeda, the director of Bristol Myers Squibb (BMS)'s business development, search and evaluation for Japan and Asia, explained so during the Seoul International